Stocks
Genmab A/SGMAB
NASDAQHealthcareBiotechnology$26.14-1.62%
Price as of · delayed, not real-time
A biotechnology firm focused on developing antibody therapeutics for cancer treatment, Genmab has partnered with major pharmaceutical companies to commercialize its innovations. Investors monitor its pipeline progress and royalty streams from blockbuster drugs like Darzalex.
Market Cap: $16.1B52W Range: $17.23 – $35.43
Congressional Interest in Genmab A/S (GMAB)
7 members of Congress have disclosed 17 trades in Genmab A/S (GMAB), a Healthcare company. The buy/sell breakdown shows 9 purchases versus 8 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
17
Unique Politicians
7
Buys
9
Sells
8
Who in Congress Is Trading GMAB?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2026-03-30 | Alan Armstrong | buy | $1K – $15K |
| 2025-04-15 | Rohit Khanna | buy | $1K – $15K |
| 2025-01-16 | Josh Gottheimer | buy | $1K – $15K |
| 2024-12-16 | Josh Gottheimer | sell | $1K – $15K |
| 2024-07-19 | Josh Gottheimer | buy | $1K – $15K |
| 2024-06-18 | Josh Gottheimer | sell | $1K – $15K |
| 2023-10-16 | Josh Gottheimer | buy | $1K – $15K |
| 2023-09-15 | Josh Gottheimer | sell | $1K – $15K |
| 2023-07-20 | Josh Gottheimer | buy | $1K – $15K |
| 2023-07-19 | Josh Gottheimer | buy | $1K – $15K |
| 2023-07-10 | Daniel Goldman | sell | $50K – $100K |
| 2023-03-31 | Daniel Goldman | sell | $1K – $15K |
| 2020-11-20 | Thomas R Carper | buy | $1K – $15K |
| 2019-05-28 | Mikie Sherrill | sell | $1K – $15K |
| 2018-12-17 | JAMES B. RENACCI | sell | $15K – $50K |
| 2018-12-12 | JAMES B. RENACCI | sell | $15K – $50K |
| 2018-02-28 | JAMES B. RENACCI | buy | $1K – $15K |